SCHEMBL4019162

SCHEMBL4019162

Brc1ccc2noc(-c3ccccc3)c2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.66
KMT2A Q03164 4/20 0.66
ALDH1A1 P00352 7/20 0.66
SMN1; SMN2 Q16637 2/20 0.66
HPGD P15428 1/20 0.66
IP6K1 Q92551 11/20 0.60
IP6K2 Q9UHH9 8/20 0.60
IP6K3 Q96PC2 7/20 0.60
KDM4E B2RXH2 3/20 0.60
TP53 P04637 2/20 0.60
HSD17B10 Q99714 2/20 0.60
NPC1 O15118 2/20 0.60
POLB P06746 1/20 0.60
MAPT P10636 2/20 0.58
RAB9A P51151 2/20 0.58
TSHR P16473 2/20 0.55
LMNA P02545 2/20 0.54
USP2 O75604 1/20 0.54
ALOX15 P16050 1/20 0.54
MAPK1 P28482 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3846806 0.83 MEN1 (0.67) MEN1KMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL1757999 0.83 ALDH1A1 (0.61) MEN1KMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL10982180 0.81 MAPT (0.61) MEN1KMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL8589245 0.80 MEN1 (1.00) MEN1KMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL26565408 0.79 KMT2A (0.73) MEN1KMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL10396461 0.79 ALDH1A1 (0.66) MEN1KMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL10933962 0.79 ALDH1A1 (1.00) MEN1KMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL10396405 0.79 ALDH1A1 (0.60) MEN1KMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL9926035 0.78 IP6K1 (0.64) MEN1KMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL10839597 0.78 IP6K1 (0.64) MEN1KMT2AALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1740640-B1 DIBENZODIAZOCINE POLYMERS SOLVAY SPECIALTY POLYMERS USA L L C (US) 2012-06-13 EP disclosed
US-20110059948-A1 QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATIVES AS ANTI-MYCOBACTERIAL AGENTS THE INSTITUTE OF MOLECULAR MEDICINE (IN) 2011-03-10 US disclosed
US-20110059948-A1 QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATIVES AS ANTI-MYCOBACTERIAL AGENTS THE INSTITUTE OF MOLECULAR MEDICINE (IN) 2011-03-10 US disclosed
US-20110059948-A1 QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATIVES AS ANTI-MYCOBACTERIAL AGENTS THE INSTITUTE OF MOLECULAR MEDICINE (IN) 2011-03-10 US disclosed
WO-2009091324-A1 QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATES AS ANTI-MYCOBACTERIAL AGENTS CHATTOPADHYAYA JYOTI (SE) 2009-07-23 WO disclosed
US-7238771-B2 Dibenzodiazocine polymers SOLVAY ADVANCED POLYMERS, L.L.C. (US) 2007-07-03 US disclosed
US-7238771-B2 Dibenzodiazocine polymers SOLVAY ADVANCED POLYMERS, L.L.C. (US) 2007-07-03 US disclosed
US-7196094-B2 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-27 US disclosed
US-4579679-A Electroactive polymers CHEVRON RESEARCH COMPANY (US) 1986-04-01 US disclosed
EP-0126064-A4 ELECTROACTIVE POLYMERS. CHEVRON RES (US) 1985-07-01 EP disclosed
US-4519937-A DOPED UNITS OF A FUSED NITROGEN-CONTAINING UNSATURATED HETEROCYCLIC RING CHEVRON RESEARCH COMPANY (US) 1985-05-28 US disclosed
US-4519938-A TRACTABLE, DOPED HETEROCYCLIC RINGS CHEVRON RESEARCH COMPANY (US) 1985-05-28 US disclosed
EP-0126064-A1 ELECTROACTIVE POLYMERS CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) 1984-11-28 EP disclosed
WO-1984002030-A1 ELECTROACTIVE POLYMERS CHEVRON RES (US) 1984-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059948-A1 QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATIVES AS ANTI-MYCOBACTERIAL AGENTS NQO1, NQO2, NDUFV1 MEN1 1176/4885KMT2A 3953/4885ALDH1A1 1830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.